Skip to content
Study details
Enrolling now

Ketamine for Opioid Use Disorder

University of Maryland, Baltimore
NCT IDNCT06943859ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

50

Study length

about 3.6 years

Ages

18–65

Locations

1 site in MD

What this study is about

Researchers are testing if ketamine helps reduce opioid cravings in adults starting methadone treatment. The trial also investigates whether low doses of ketamine improve symptoms like depression and pain, and whether it leads to better treatment outcomes compared to a very low dose.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Treatment with Ketamine
  • 2.Take Treatment with Very Low Dose Ketamine

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia), anesthetic (NMDA receptor antagonist; induces dissociative anesthesia and analgesia)

Endpoints

Secondary: Chronic pain ratings, Insomnia Symptoms, Severity of depression symptoms, Sleep quality ratings on a Visual Analogue Scale (VAS)

Body systems

Psychiatry / Mental Health